Long-term potency after early use of a vacuum erection device following radical prostatectomy
Article first published online: 15 NOV 2010
© 2010 THE AUTHORS. JOURNAL COMPILATION © 2010 BJU INTERNATIONAL
Volume 106, Issue 11, pages 1719–1722, December 2010
How to Cite
Raina, R., Pahlajani, G., Agarwal, A., Jones, S. and Zippe, C. (2010), Long-term potency after early use of a vacuum erection device following radical prostatectomy. BJU International, 106: 1719–1722. doi: 10.1111/j.1464-410X.2010.09360.x
- Issue published online: 15 NOV 2010
- Article first published online: 15 NOV 2010
- Accepted for publication 12 January 2010
- prostate cancer;
- vacuum erection device;
- radical prostatectomy
Study Type – Prognosis (case series) Level of Evidence 4
To evaluate the long-term potency after radical prostatectomy (RP) with the early use of a vacuum erection device (VED), and reasons for sexual inactivity and long-term attrition and maintenance of sexual activity, as RP is one of the most common treatments for prostate cancer but erectile dysfunction (ED) is a common side-effect.
PATIENTS AND METHODS
We identified 141 sexually active patients who underwent RP at Cleveland Clinic Foundation. Patients were offered various non-oral treatment options to prevent ED and were also motivated for early penile rehabilitation. At 5 years 62% remained sexually active, of whom 71% had natural erections sufficient for intercourse without assistance, 8.5% were still using sildenafil, 10% were using combined therapy (sildenafil plus VED). At 5 years 38% (43/113) men were sexually inactive. The reasons included loss of interest in 17 (40%), cardiovascular/neurological diseases in 18 (42%), hormonal therapy in three (7%), loss of partner in three (7%) and two had other surgery. The natural rate of erections for sufficient vaginal penetration without an erection aid were preserved and maintained in the early-prophylaxis group, and almost 60% of them had used a VED as early prophylaxis.
Despite current phosphodiesterase-5 inhibitor treatments for ED, VED is becoming recognized again as having a primary role in early penile rehabilitation in many patients, specifically those treated for prostate cancer.